Risk assessment for adverse drug reactions
    348.
    发明授权
    Risk assessment for adverse drug reactions 有权
    不良药物反应的风险评估

    公开(公告)号:US09562268B2

    公开(公告)日:2017-02-07

    申请号:US13966996

    申请日:2013-08-14

    CPC classification number: C12Q1/6881 C12Q1/6883 C12Q2600/156 G01N33/94

    Abstract: The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test.

    Abstract translation: 本发明提供了一种预测患者发展不良药物反应(特别是SJS或TEN)的风险的方法。 发现HLA-B等位基因HLA-B * 1502与由各种药物诱导的SJS / TEN相关。 与HLA-B * 1502的相关性对于卡马西平诱导的SJS / TEN是最显着的,其中所有测试的患者具有HLA-B * 1502等位基因。 另外HLA-B等位基因HLA-B * 5801与别嘌呤醇诱导的SJS / TEN特别相关。 特别是与第三等位基因HLA-B * 4601相关的皮肤反应较轻,如斑丘疹,多形性红斑,荨麻疹和固定药物爆发。 对于任何等位基因,位于特异性HLA-B单倍型的DRB1和HLA-A区之间的遗传标记(例如HLA标记,微卫星或单核苷酸多态性标记)也可用于测试。

    USE OF PEPTIDE FOR ALLEVIATING PAIN
    349.
    发明申请
    USE OF PEPTIDE FOR ALLEVIATING PAIN 有权
    使用肽来改善疼痛

    公开(公告)号:US20160346348A1

    公开(公告)日:2016-12-01

    申请号:US14723914

    申请日:2015-05-28

    CPC classification number: A61K38/1706

    Abstract: The present invention relates to a method for alleviating pain in a subject in need thereof, which comprises administering an effective amount of piscidin (PCD) peptide and a pharmaceutically acceptable carrier to the subject.

    Abstract translation: 本发明涉及一种减轻有需要的受试者疼痛的方法,其包括将有效量的皮屑(PCD)肽和药学上可接受的载体给予受试者。

    Automatic amino acid sequencing of glycopeptide by Y1 ions
    350.
    发明授权
    Automatic amino acid sequencing of glycopeptide by Y1 ions 有权
    通过Y1离子自动氨基酸测序糖肽

    公开(公告)号:US09484193B2

    公开(公告)日:2016-11-01

    申请号:US14298911

    申请日:2014-06-07

    CPC classification number: H01J49/0031 G01N33/6818 G01N33/6851 H01J49/0054

    Abstract: Apparatus and methods for automatic amino acid sequencing of a glycopeptide by mass spectrometry. The glycopeptide is fragmented by higher energy collision dissociation fragmentation, and sequentially fragmented by collision induced dissociation fragmentation. The glycopeptide Y1 ion is isolated, and the mass spectra of fragmented glycopeptide Y1 ions provide mass spectral peaks corresponding to the amino acid sequence of the glycopeptide.

    Abstract translation: 通过质谱法对糖肽进行自动氨基酸测序的装置和方法。 糖肽通过较高的能量碰撞解离断裂而碎裂,并通过碰撞诱导的解离片段依次碎裂。 分离糖肽Y1离子,碎片糖肽Y1离子的质谱提供对应于糖肽的氨基酸序列的质谱峰。

Patent Agency Ranking